It has been another positive session for the CSL Limited (ASX: CSL) share price.
At the time of writing, the biotherapeutics companyâs shares are up 1% to a 52-week high of $304.75.
As you can see below, this means the CSL share price is now up 16% since this time last year.
Why is the CSL share price hitting a 52-week high?
As well as getting a boost from a rising share market today, investors have been buying the companyâs shares due to the release of a series of positive broker notes.
One of those came from Morgans yesterday, with its analysts adding CSL to its best ideas list for February. Morgans has an add rating and $312.20 price target on its shares.
The broker believes that 2023 could be the break-out year for CSL after facing some challenging times during the pandemic. The broker commented:
A key portfolio holding and key sector pick, we believe CSL is poised to break-out this year, a COVID exit trade, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares offering good value trading around its long term forward multiple of 31.5x.
Elsewhere, analysts at Morgan Stanley believe the CSL share price can climb even higher. Yesterday, the broker reiterated its overweight rating and $354.00 price target. This implies potential upside of 16% from its 52-week high.
All in all, this could just be one of many new 52-week highs the companyâs shares make in 2023 if Morgan Stanley is on the money with its recommendation.
The post CSL share price surges to new 52-week high on Thursday appeared first on The Motley Fool Australia.
FREE Guide for New Investors
Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…
For over a decade, we’ve been helping everyday Aussies get started on their journey.
And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.
Yes, Claim my FREE copy!
*Returns as of February 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- How Iâd invest $20k in ASX 200 shares in 2023 to aim for a million
- Should I buy CSL shares before this month’s earnings update?
- ‘Incredibly cheap’: 2 ‘strong’ ASX shares expert would pounce on right now
- 3 ASX shares I dream of owning at the right price
- Jun Bei Liu’s 2 ‘structural growth’ ASX shares to buy now
Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/mwt69je
Leave a Reply